In a recent article, I described how exercising muscles act as endocrine organs, releasing hormone-like molecules called myokines that slow cancer cell division, trigger cancer cell death, and sharpen immune surveillance. That piece, “Myokines: How Exercise Fights Cancer,” made the case that muscle is not merely an engine for movement but a producer of medicine. A newly published study in Nature Communications reveals a second, distinct mechanism by which active muscle fights cancer, one that works alongside myokines rather than through them.
The new mechanism involves tiny membrane-wrapped packages called extracellular vesicles.
What Are Extracellular Vesicles?
Cells throughout the body communicate not only by secreting free-floating molecules but also by releasing small, sealed capsules that carry a curated cargo of proteins and genetic material. These extracellular vesicles, often called exosomes when they fall in the smallest size range of roughly 100 nanometers, bud off from cells and travel through the bloodstream to distant tissues. When a vesicle reaches a recipient cell, it can be taken up whole, delivering its contents directly into that cell’s interior. This is a far more targeted form of communication than a hormone diffusing through the bloodstream, because the vesicle protects its cargo and can be selectively recognized by particular tissues.
Skeletal muscle, it turns out, is a prolific producer of these vesicles, and the packages it sends carry a potent anti-cancer payload.
The Central Discovery
Researchers at Duke-NUS Medical School in Singapore, working with fruit flies, mice, and human cancer cell lines, demonstrated that vesicles secreted by young, healthy muscle cells suppress tumor growth, whereas vesicles from aged or damaged muscle cells lose this protective power. The team showed that muscle vesicles were taken up by colorectal, cholangiocarcinoma (bile duct), and lung cancer cells, and that this uptake reduced cancer cell proliferation and triggered cancer cell death. In living mice, delivering healthy muscle vesicles into tumors slowed their growth, cut the fraction of dividing cancer cells, and increased cancer cell death. Vesicles from damaged muscle produced no such benefit.
Perhaps the most striking experiment blocked the production of muscle vesicles in young, healthy mice. When the researchers used a drug to shut down vesicle secretion in the thigh muscles, tumors in those animals grew substantially larger, with more proliferation and less cell death. Restoring the vesicles reversed the effect. Healthy muscle, in other words, is actively restraining tumor growth at all times, and removing that restraint lets cancer accelerate.
The Active Ingredient: A Tumor-Suppressing microRNA
The researchers went on to identify what inside these vesicles does the work. The key cargo is a small piece of regulatory genetic material called miR-7a-5p, a microRNA that acts as a molecular brake on genes that drive cancer. This microRNA is evolutionarily conserved from flies to humans and has been described as a tumor suppressor across several cancer types, including colorectal, gastric, liver, and skin cancers.
In cancer cells, miR-7a-5p targets and silences the TEAD1 gene. TEAD1 is a partner protein in the Hippo signaling pathway, a growth-control system that, when dysregulated, allows cancer cells to proliferate unchecked. By suppressing TEAD1, muscle-delivered miR-7a-5p throttles the machinery that cancer cells use to multiply. When the researchers delivered a synthetic version of this microRNA directly into tumors, they saw the same tumor-shrinking effect, confirming that miR-7a-5p is the operative agent.
Why Aging Muscle Loses Its Protective Power
The study’s most clinically relevant thread concerns sarcopenia, the progressive loss of muscle mass and strength that accompanies aging. Sarcopenia is already recognized as an independent predictor of poor survival across most cancers, and a recent cohort study found that people with pre-existing sarcopenia face an elevated risk of developing lung, colorectal, gastric, pancreatic, and esophageal cancers. Until now, the biological reason for this link was unclear.
This research supplies the missing mechanism. Aging muscle produces fewer vesicles, and the vesicles it does produce carry much less of the protective miR-7a-5p. The team traced this decline to a protein called SDC2 (syndecan-2), which is required for muscle to package and release vesicles properly. As muscle ages, SDC2 levels fall, vesicle production drops, and the anti-cancer signal fades. The result is a muscle that has gone quiet, no longer sending its tumor-suppressing packages into circulation.
Where Exercise Enters the Picture
Here, the story returns to physical activity. SDC2 production is controlled upstream by the Notch signaling system, which is known to decline with age but can be reawakened by exercise and muscle contraction. The researchers hypothesized that exercise might restore the entire chain: reactivate Notch, raise SDC2, restore vesicle production, replenish miR-7a-5p, and suppress tumor growth.
That is precisely what they found. When aged mice were put through a combined treadmill and running-wheel exercise program, their muscles regained Notch activity, produced more vesicles, restored miR-7a-5p levels, and suppressed tumor growth. The exercising animals also lost fat mass and gained lean muscle. Critically, when the researchers blocked either the Notch signal or the SDC2 protein, exercise lost its anti-cancer benefit, proving that this specific pathway carries the effect.
Two Complementary Arms of a Single Truth
Taken together with the myokine research, a fuller picture emerges. When you contract your muscles, they defend you against cancer through at least two parallel channels. The first, described in my earlier article, is the release of myokines, free-floating signaling molecules that slow cancer growth, induce cancer cell death, and enhance immune surveillance. The second, described here, is the secretion of extracellular vesicles carrying miR-7a-5p, molecular packages that dock with cancer cells and silence the genes driving their proliferation. Both channels weaken with age and muscle loss, and both can be restored through physical activity.
The practical message aligns closely with what I have written before. Preserving muscle mass is not a cosmetic goal or a matter of strength alone. Muscle is a metabolic and secretory organ that actively participates in the body’s defense against malignant disease. Resistance training and regular movement keep that organ productive, maintaining the flow of both myokines and tumor-suppressing vesicles into the bloodstream.
This is one more reason to view the loss of muscle with age not as an inevitable cosmetic decline but as a meaningful erosion of one of the body’s built-in cancer defenses. The encouraging truth is that this erosion is not fixed. The same muscle contractions that build strength also restart the anti-cancer signaling that aging quiets, a reminder that our bodies were designed with remarkable capacities for self-repair, and that faithful stewardship of the body we have been given pays dividends we are only beginning to understand.
References
- Ashcraft KA, Peace RM, Betof AS, Dewhirst MW, Jones LW. Efficacy and mechanisms of aerobic exercise on cancer initiation, progression, and metastasis: a critical systematic review of in vivo preclinical data. Cancer Res. 2016;76(14):4032-4050.
- Au PC, Li HL, Lee GK, et al. Sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia. 2021;7(Suppl 1):S28-S33.
- Baietti MF, Zhang Z, Mortier E, et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14(7):677-685.
- Chen J, Zhou R, Feng Y, Cheng L. Molecular mechanisms of exercise contributing to tissue regeneration. Signal Transduct Target Ther. 2022;7(1):383.
- Goh KY, Lee WX, Gou Q, et al. Sarcopenia promotes tumorigenesis by disrupting NOTCH-SDC2-regulated biogenesis of muscle-derived extracellular vesicles. Nat Commun. 2026.
- Morales-Martinez M, Vega MI. Role of microRNA-7 (MiR-7) in cancer physiopathology. Int J Mol Sci. 2022;23(16):9091.
- Sun MY, Chang CL, Lu CY, Wu SY, Zhang JQ. Sarcopenia as an independent risk factor for specific cancers: a propensity score-matched Asian population-based cohort study. Nutrients. 2022;14(9):1910.
- Zhao N, Liu H, Lilly B. Reciprocal regulation of syndecan-2 and Notch signaling in vascular smooth muscle cells. J Biol Chem. 2012;287(20):16111-16120.
